Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
EGFR-mutated LUSC patients receiving EGFR-TKIs treatment had higher ORR and longer PFS than EGFR wild-type LUSC patients.
Authors
- J. Gong (ORCID: https://orcid.org/0000-0002-7299-883X)
- Hongyang Lu (ORCID: https://orcid.org/0000-0003-0404-5153)
- Shumin Hu (ORCID: https://orcid.org/0000-0001-7889-9309)
- Lingru Chen
- Zhixin Chen
- Lan Yang (ORCID: https://orcid.org/0000-0003-3252-3300)
- Jing Chen (ORCID: https://orcid.org/0000-0003-1894-335X)
Institutions
- Zhejiang Chinese Medical University (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Ningbo No. 2 Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1080/07853890.2025.2488109
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07